Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,391 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Viral Infection Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of the COVID-19 Health Emergency on Biopsychosocial Health

NCT04409535
View directory record Official record
Conditions
Activities, Mental Health Issue, Life Style
Interventions
WHOQOL-BREF survey
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Nebulized Hypertonic Saline for Bronchiolitis

NCT00619918
View directory record Official record
Conditions
Bronchiolitis
Interventions
Nebulized 3% saline, Nebulized 0.9% saline
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 24 Months
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 22, 2026, 7:32 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04338360
View directory record Official record
Conditions
COVID19
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

NCT07225959
View directory record Official record
Conditions
Healthy Participants
Interventions
MK-1406 Injection
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 66 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami Lakes, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

NCT00632463
View directory record Official record
Conditions
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
Interventions
RI-001
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

NCT02670187
View directory record Official record
Conditions
Healthy
Interventions
GLS-5300
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Awake Prone Position for Early Hypoxemia in COVID-19

NCT04344587
View directory record Official record
Conditions
COVID-19
Interventions
Self-prone position recommendation, Usual care
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Long Beach, California • San Diego, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting No phase listed Observational

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

NCT06813872
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
ABRYSVO Vaccination
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Months to 6 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flucelvax (TIVc or QIVc) Pregnancy Registry

NCT03438487
View directory record Official record
Conditions
Influenza, Human, Pregnancy, Birth Defect
Interventions
Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
Female only
Enrollment
692 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Fostamatinib for Hospitalized Adults With COVID-19

NCT04579393
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

NCT04498741
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Project ECHO in Nursing Homes

NCT04499391
View directory record Official record
Conditions
Covid19
Interventions
Project ECHO
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 22, 2026, 7:32 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

NCT00216242
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Saline placebo
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2006 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

NCT00336453
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Months to 59 Months
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19

NCT04613739
View directory record Official record
Conditions
Asthma
Interventions
insurance navigation
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
4 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed No phase listed Observational

Collection and Extraction of Respiratory Specimens

NCT01083511
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Tucson, Arizona • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 22, 2026, 7:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Viral Mucosal Reprogramming

NCT05331170
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cat Allergy, Healthy
Interventions
Research Grade RG-RV
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

NCT05120869
View directory record Official record
Conditions
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Interventions
Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Cruces, New Mexico • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting Not applicable Interventional

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

NCT05102656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Discussion, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 4 Interventional

Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting

NCT04621461
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Zinc Sulfate 220 MG, Placebo
Dietary Supplement · Drug
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 22, 2026, 7:32 AM EDT